Pharmaceutical

Iptacopan hydrochloride by Novartis for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis): Likelihood of Approval

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Granulomatosis with Polyangiitis (Wegener's Granulomatosis).

Dec 31, 2024 - 06:00
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Granulomatosis with Polyangiitis (Wegener's Granulomatosis).
Read the original article

Tags:

Previous Article

Tevimbra by BeiGene for Gallbladder Cancer: Likelihood of Approval

Next Article

CT-7439 by Carrick Therapeutics for Breast Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Which drugs are most likely to be approved in Tenosynov...

Mar 28, 2024

Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may lead to a Comirnaty monopoly

Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may le...

Jun 3, 2023

STAT+: ‘Shocking’ heat waves persist through August as federal officials warn of far-ranging health risks

STAT+: ‘Shocking’ heat waves persist through August as ...

Aug 7, 2023